Manish A Shah, M.D.
The Gastrointestinal Oncology program at Weill Cornell Medical College/ New York-Presbyterian Hospital offers a comprehensive, multi-disciplinary approach to patients with cancers of the gastrointestinal tract. Gastrointestinal malignancies are among the most common cancers in the United States and around the Globe. Patients with cancers of the GI tract often require expertise across a broad range of disciplines. We are committed to providing personalized and coordinated care in an effort to maximize patient outcomes while minimizing potential side effects of therapy. Advancing the treatment of patients with gastrointestinal malignancies is central to the mission of the Gastrointestinal Oncology Program within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care. Additionally, by improving our understanding of the biology of these diseases, including genetic and environmental risks, the role of inflammation and the tumor microenvironment in the development and progression of disease, we hope to improve our ability to prevent, diagnose, and treat these complex diseases.
Dr. Shah graduated from Johns Hopkins University in 1991 with a Bachelor's of Science degree in Biomedical Engineering, and from Harvard Medical School/MIT Health Sciences and Technology program in 1996, graduating magna cum laude, with a Medical Doctorate degree. He completed his Internal Medicine Residency training at Duke University Medical Center in 1999, and his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in 2001, also serving as Chief Oncology Fellow. He is the recipient of several awards including the American Society of Clinical Oncology Young Investigator and Career Development Awards. He was recruited from Memorial Sloan Kettering Cancer Center to Direct the Gastrointestinal Oncology Program within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care at Weill Cornell Medical College / New York-Presbyterian Hospital.
Dr. Shah is a national and international thought leader in drug development and the treatment of gastrointestinal malignancies. He is a distinguished peer-review funded investigator and has led several Phase I, II and III clinical trials in patients with advanced gastric cancer. Dr. Shah is also the Director of the Gastrointestinal Oncology Research Laboratory at Weill Cornell Medical College. His areas of translational research interests are in improving our understanding of cancers of the upper GI tract as well as hereditary gastrointestinal malignancies. He is interested in power of genomic evaluations of malignancy and how the environment and personal risks can impact the genetic causes of malignancy. He is a peer-reviewer for NIH and NCI research funding, and a reviewer for several high impact journals including the Journal of the American Medical Association, Journal of Clinical Oncology, Annals of Surgery, Annals of Surgical Oncology, Clinical Cancer Research and Gastroenterology. Dr. Shah is also the Editor for The Management of Complex Cases in Gastrointestinal Oncology Case Series for the Journal Of Gastrointestinal Oncology and the Series Editor for the Dx/RX: Oncology Series published by Jones and Bartlett Publishers. He has authored several books including Dx/Rx: Upper Gastrointestinal Malignancies: Cancers of the Stomach and Esophagus, as well as 100 Questions and Answers about Stomach Cancer. He is a member of the American Society of Clinical Oncology (serving as a Cancer Education Committee Member), American Association of Cancer Research, and the American Gastroenterology Association. In addition, Dr. Shah is Chair of the Scientific Advisory Board for the DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research.
Dr. Shah and the Gastrointestinal Oncology group are committed to providing excellent and personalized care for you and your loved ones. We would welcome the opportunity to take part in your care, whether it involves primary management or for consultation in conjunction with your treating physicians. Ensuring you are receiving the best and most comprehensive treatment for your malignancy is our aim. Please feel free to contact us for an appointment, or have your physician contact us to discuss your care.
Johns Hopkins University (Baltimore MD) B.E.S. Biomedical Engineering 1987 – 1991
Harvard Medical School / Health Sciences and Tech (Boston, MA) MD1991 – 1996
PROFESSIONAL POSITIONS AND EMPLOYMENT
Duke University Medical Center (Durham NC) Internal Medicine Internship 1997
Duke University Medical Center (Durham NC) Internal Medicine Residency 1998-1999
Memorial Sloan-Kettering Cancer Center (NY NY) Medical Oncology Fellow 1999-2001
Memorial Sloan-Kettering Cancer Center (NY NY) Cheif Fellow 2000-2001
Joan and Sanford I. Weill Medical College (NY NY) Fellow in Medicine 1999-2001
PROFESSIONAL MEMBERSHIPS (medical and scientific societies)
Member Cancer and Leukemia Group B (CALGB) 2000-present
Member American Assoc of Cancer Res (AACR) 2000-present
Member American Society of Clin Onc (ASCO) 2000-present
Member American Gastroenterological Association (AGA) 2010-present
Member European Society of Medical Oncology (ESMO) 2010-present
Member Massachusetts Medical Society 1994-1996
Member Tau Beta Pi (Nat'l Engineering Honor Society) 1988-1991
President Tau Beta Pi (JHU Chapter) 1990-1991
EXTRAMURAL PROFESSIONAL RESPONSIBILITIES
NCI External Review Committee – Sept 2005
National Cancer Research Network (United Kingdom, Dept of Health) – Expert External Review Committee – Sept 2005, June 2009
The DeGregorio Family Foundation for Gastroesophageal Cancer, Chair, Scientific Advisory Board – January 2007-present
Peer Review Faculty Reviewer for 2009-present ASCO Educational Book
NIH/ NCI Study Section Member – Panel ZRG1 OTC-K(53) - provide peer review for NICH grant applications in drug delivery for cancer therapy, chemotherapy, and clinical trials.
NIH SBIR Study Section – October 2009 to present
Editorial Board of International Journal of Gastrointestinal Cancer
Case Series Editor – Management of Complex Cases in GI Oncology
2011-2013 ASCO Upper GI Educational Committee Member
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Medicare [Medicare]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [Medicare]
- VNSNY CHOICE Medicare [HMO]
Selected Peer-Reviewed Manuscripts:
Huntington's Disease Collaborative Research Group (33rd out of 58 total authors). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease Chromosomes. Cell 1993; 72(6):971-983.
Gopal AK, Fowler VG Jr., Shah M, Gesty-Palmer D, Marr KA, McClelland S, Kong LK, Gottlieb GS, Lanclos K, Li J, Sexton DJ, Corey GR. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. Journal of Clinical Oncology 2000;18(5):1110-15.
Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK. Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. Clinical Cancer Research 2001;7:4209-19.
Shah MA, Sanders L, Wray D, Lanclos K, Chamis A, Corey RG, Gockerman J, and Fowler, VG Jr. Staphylococcus aureus bacteremia in patients with neutropenia. Southern Medical Journal 2002 Jul;95(7):782-4.
Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Brit J Cancer 2004;90(9):1720-6.
Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A phase I clinical trial of the sequential combination of irinotecan and flavopiridol: toxicity, efficacy, and biological correlates., Clinical Cancer Research 2005;11(10):1439-45.
Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, Gonen M, Schwartz GK. Drg1 expression in 131 colorectal liver metastases: Correlation with clinical parameters and patient outcomes., Clinical Cancer Research, 2005;11(9):3836-45.
Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005;23(9):1875-84.
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 2005;23(9):1803-10.
Shah MA, Ramanathan KR, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. A multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal adenocarcinoma. J Clin Oncol, 2006;24(33):5201-6.
Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP. A Phase II trial of neoadjuvant cisplating-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 2006;17(9):1404-11.
Asmis TA, Capanu M, Kelsen DP, Shah MA. Systemic Chemotherapy does not increase the risk of gastrointestinal perforation. Ann Oncol 2007;18(12):2006-8.
Mansour JC, Tang L, Shah MA, Bentrem D, Klimstra DS, Kelsen DP, Brennan MF, Coit DG. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 2007;14(12):3412-8.
Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cell lines. Mol Cancer Ther 2008;7(11):3499-508.
Steinberg ML, Hwang BJ, Tang L, Shah MA. E cadherin gene alterations in gastric cancers in different ethnic populations. Ethn Dis. 2008;18(2 Suppl 2):S2-70-4.
Ku GY, Ilson DI, Schwartz LH, Capanu M, O'Reilly M, Shah MA, Kelsen DP, Schwartz, GK. Phase II trial of sequential paclitaxel and one hour infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008;62(5):875-80.
Asmis TA, Chung KY, Teitcher JB, Kelsen DP, Shah MA. Pneumotosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 2008;26(1):95-6.
Rathkopf D, Dickson MA, Feldman DR, Carvajal RD, Shah MA, Wu N, Lefkowitz R, Gonen M, Cane LM, Dials HJ, Winkelmann JL, Bosl GJ, Schwartz GK. Phase I Study of flavopirdol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res. 2009 Dec 1;15(23):7405-11. Epub 2009 Nov 24.
Power DG, Shah MA, Asmis TR, Garcia JJ, Kemeny NE. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs. 2010;28(3):353-60. Epub 2009 May 26.
Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly EM. A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology. 2009 May 19;9(4):404-9.
Power DG, Schattner MA, Gerdes H, Brenner B, Markowitz AJ, Capanu M, Coit DG, Brennan M, Kelsen DP, Shah MA. Endoscopic Ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Amer Coll of Surg 2009;208(2):173-78.
Jhawer M, Coit D, Brennan M, Qin L, Gonen M, Klimstra D, Tang L, Kelsen DP, Shah MA. Perineural invasion following preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic correlation. Am J Clin Oncol. 2009 Aug;32(4):356-62.
Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, Coit DG, Brennan MF. Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram. Ann Surg. 2010;251(4):640-6.
Lurje G, Husain H, power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann. Oncol. 2010 Jan;21(1):78-86.
Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. The Clinical Significance of the development of VTE in Upper Gastrointestinal Malignancies. J Thrombosis & Hemostasis 2010; 8(8):1702-9.
Shah MA and Ajani JA. Gastric Cancer: An Enigmatic and heterogeneous disease where quandaries abound. JAMA Editorial 2010;303(17):1753-4.
Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. A multicenter phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal adenocarcinoma. Invest New Drugs 2010;[epub ahead of print] June 25 2010
Fitzgerald RC, Hardwick R, Huntsman D, et al (1 of 53 collaborators); International Gastric Cancer Linkage Consortium. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010;47(7):436-44.
Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 2010;[epub ahead of print] June 29 2010.
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011;117(7):1409-14.
Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol. 2010;66(6):1113-21.
Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. A phase II study of modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29(7):868-74. Epub 2010 Dec 28.
Winder T, Bohanes P, Zhang W, Yang D, Power DG, Ning Y, Greger A, Wilson PM, Tang LH, Shah M, Lee AS, Lenz HJ. GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. Ann Oncol. 2011 Mar 7 [Epub ahead of print].
Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers. 2011;20(5):1021-7. 2011, Mar 10 [Epub ahead of print]
Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP. Molecular classification of gastric cancer: a new paradigm. Clinical Cancer Res. 2011;17(9):2693-701 2011, Mar 23 [Epub ahead of print].
Fields RC, Strong VE, Gonen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. Br J Cancer 2011;104(12):1840-7. 2011 May 24[Epub ahead of print]
Shah MA, Salo-Mullen E, Stadler Z, Ruggeri JM, Mirander M, Pristyazhnuk Y, Zhang L. De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer. Clin Genet 2011 Jun 23[Epub ahead of print]
Research for Electrical Energy Systems - An Annual Report ed. William E. Anderson Chapter 2: Gaseous Dielectric Research. Van Brunt R, Olthoff J, Stricklett K, Herron J, Shah MA, Wan H, Moore J. June, 1992.
The function of neuron specific kinesin heavy chain as assessed by antisense technology, by Manish A. Shah (thesis), February 1996:1-56, Publ Harvard Medical School.
Shah MA and Schwartz GK. The relevance of sequence in combination chemotherapy. Drug Resistance Updates 2000 Dec;3(6):335-356
Shah MA and Schwartz GK. Cell cycle mediated drug resistance: An emerging concept in cancer therapy. Clinical Cancer Research 2001;7(8):2168-2181.
Shah MA. Recent developments in the treatment of gastric carcinoma. Current Oncology Reports 2002 May;4(3):193-201
Shah MA and Kelsen DP. Post-operative adjuvant chemoradiotherapy in high risk gastric cancer. Chirurg 2002 April;73(4):325-30.
Shah MA and Schwartz GK. Cell Cycle Modulation: An Emerging Target for Cancer Therapy. Horizons in Cancer Therapeutics: From Bench to Bedside 2003;4(3):3-21.
Shah MA and Schwartz GK. Cancer Chemotherpay and Biological Response Modifiers, Annual 21. Eds. Giaccone, Schilsky, Sondel. Cyclin-dependent kinases as targets for cancer therapy. 2003, p145- 170.
Shah MA and Kelsen DP. Treating Colorectal Cancer. Coping, March/April 17(2):39-40, 2003.
Shah MA and Schwartz GK. The Treatment of Metastatic Esophagus and Gastric Cancer, Seminars of Oncology, 2004 Aug; 31(4):574-587.
Schwartz GK and Shah MA. Targeting the cell cycle: a new approach to cancer therapy. Journal of Clin Oncol 2005;23(36):9408-21.
Shah MA and Schwartz GK. Cancer Chemotherpay and Biological Response Modifiers, Annual 22. Eds. Giaccone, Schilsky, Sondel. Cyclin-dependent kinases as targets for cancer therapy. 2005;22:135-62.
Shah, MA. Gastric cancer: an update. Curr Oncol Rep. 2006 May;8(3):183-91.
Jhawer M, Kelsen DP, and Shah MA. Incorporation of biologic therapies in the management of gastroesophageal cancers. Gastrointest Cancer Res 2007; 1(2):(suppl 1)S22-S29.
Shah, MA. Bevacizumab with chemotherapy in the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The American J of Hematology/Oncology. 2007 June;6(6):355-58.
Shah MA. and Kelsen DP. The Molecular Basis of Gastric and Gastroesophageal Adenocarcinoma. Molecular Basis of Cancer, Ed 3. Eds. Mendelsohn, Howley, Thompson, Grey, and Israel. 2008; Chapter 42, p511-520. Publ Saunders Elsevier, Philadelphia PA.
Asmis TR and Shah MA. Gastrointestinal Oncology: Medical Oncology. Principals and Practice of Gastrointestinal Oncology, Ed 2. Eds. Kelsen, Daly, Kern, Levin, Tepper, and Van Custem. 2nd Ed 2008;Chapter 7, p81-87. Publ Lippincott Williams &Wilkins, Philadelphia PA.
Shah M, Strong V. Cancer of the stomach. CCO Oncology in Practice. 2009. Available at: www.clinicaloptions.com.
Mezhir JJ, Pillarisetty VG, Shah MA, Coit DG. Randomized clinical trials in gastric cancer. Surg Oncol Clin N Am. 2010 Jan;19(1):81-100. Review.
Shah MA and Kelsen DP. Gastric Cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compre Canc Netw. 2010;8(4):437-47.
Shah MA and Kurtz RC. Upper Gastrointestinal Genetic predisposition syndromes. Hematol Oncol Clin North Am. 2010;24(5):815-35.
Power DG, Kelsen DP, Shah MA. Advanced gastric cancer – slow but steady progress. Cancer Treat Rev 2010;36(5):384-392.
Janjigian YY, Shah MA. Molecularly targeted therapies in advanced gastric cancer. Minerva Gastroenterol Dietol 2011 Mar;57(1):75-88.
Honors and Awards
ASCO Career Development Award 2003-2006
CTEP Translational Research Initiative Award 2004
CALGB Investigator Award 2001
ASCO Young Investigator Award 2001
AACR/ASCO:Methods in Clinical Can Res Workshop 2001
AACR Scholar in Training Award 2001
National Medical Oncology Fellows Forum 2001
Berlex Oncology Foundation:
Clinical Pharmacology of Anticancer Drugs 10/2000
Clinical Epidemiology and Biostatistics 8/2000
Duke Managed Care Learning Center
Resident participant- 1997-1999
Magna cum laude - Harvard Medical School 1996
Pharmaceutical Research Award: Harvard Medical 1992-1993
National Science Foundation Undergraduate Summer
Research Fellowship, JHU 1989
- Medical Oncology
- Gastrointestinal Oncology
- Esophageal Cancer
- Gastric Cancer
- Colorectal Cancer
- Pancreas Cancer
- Liver Cancer
- Biliary Tract Cancer
- Small Bowel Cancer
- Neuroendocrine Carcinoma
- Family History of Gastric Cancer
- Family History of Colorectal Cancer
- Family History of Esophageal Cancer
- Internal Medicine
- Medical Oncology
- B.S.E., The Johns Hopkins University, 1991
- M.D., Harvard Medical School, 1996